Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.87

-1.9%

1:47 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: rkrw who wrote (12401)	7/19/2004 9:46:34 AM
From: Biomaven	Read Replies (1) of 52153

Yes, BiDil® is a combination of two old heart drugs, isosorbide dinitrate and hydralazine. Presumably they will face the standard FDA skepticism about combination drugs - i.e,, they will have to show superiority over each constituent separately. There may be also be some flak from those that don't believe in racial profiling in medicine - there was an article supporting this (contrary to the facts in my view) "equality" viewpoint in the NEJM a few years back. On the other hand going by this PR the results sound pretty good and there is a desperate need for new heart failure treatments, particularly in African Americans. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next